Chronic granulomatous disease: Complications and management

Expert Review of Clinical Immunology

Volumn 5, Issue 1, 2009, Pages 45-53

  Rosenzweig, Sergio D ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Gene therapy; Hematopoietic stem cell transplantation; Infection; Phagocyte

Indexed keywords

COTRIMOXAZOLE; GAMMA INTERFERON; ITRACONAZOLE; NAFCILLIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PLACEBO;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EARLY DIAGNOSIS; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFLAMMATION; LIFE EXPECTANCY; MYALGIA; MYCOSIS; QUALITY OF LIFE; RECURRENT INFECTION; RESPIRATORY BURST; REVIEW;

EID: 77649102460     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.5.1.45     Document Type: Review

References (77)

1. Janeway CA, Craig J, Davison M et al. Hypergammaglobulinemia associated with severe, recurrent, and chronic non-specific infection. Am. J. Dis. Child. 88, 388-392 (1954).
2. Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. Am. J. Dis. Child. 97, 387-408 (1959).
3. Segal BH, Leto TL, Gallin JI et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79, 170-200 (2000).
4. Fuchs TA, Abed U, Goosmann C et al. Novel cell death program leads to neutrophil extracellular traps. J. Cell. Biol. 176, 231-241 (2007).
5. Winkelstein JA, Marino MC, Johnston RB Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 79, 155-169 (2000).
6. Baehner RL, Kunkel LM, Monaco AP et al. DNA linkage analysis of X chromosomelinked chronic granulomatous disease. Proc. Natl Acad. Sci. USA 83, 3398-3401 (1986).
7. Nunoi H, Rotrosen D, Gallin JI, Malech HL. Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science 242, 1298-1301 (1988).
8. Volpp BD, Nauseef WM, Clark RA. Two cytosolic neutrophil oxidase components absent in autosomal chronic granulomatous disease. Science 242, 1295-1297 (1988).
9. Volpp BD, Nauseef WM, Donelson JE et al. Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase. Proc. Natl Acad. Sci. USA 86, 7195-7199 (1989).
10. Leto TL, Lomax KJ, Volpp BD et al. Cloning of a 67-kD neutrophil oxidase factor with similarity to a non-catalytic region of p60c-src. Science 248, 727-730 (1990).
11. Franke U, Hsieh CL, Foellmer BE et al. Genes for two autosomal recessive forms of chronic granulomatous disease assigned to 1q25 (NCF2) and 7q11.23 (NCF1). Am. J. Hum. Genet. 47, 483-492 (1990).
12. Dinauer MC, Pierce EA, Bruns GA et al. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutations in cytochrome-negative autosomal recessive chronic granulomatous disease. J. Clin. Invest. 86, 1729-1737 (1990).
13. Dorman SE, Guide SV, Conville PS et al. Nocardia Infection in chronic granulomatous disease. Clin. Infect. Dis. 35, 390-394 (2002).
14. Segal BH, DeCarlo ES, Kwon-Chung KJ et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 77, 345-354 (1998).
15. Sponseller PD, Malech HL, McCarthy EF Jr et al. Skeletal involvement in chronic granulomatous disease of childhood. J. Bone Joint Surg. Am. 73, 37-51 (1991).
16. Galluzzo ML, Hernandez C, Davila MTG et al. Clinical, histopathologic and a unique spectrum of organisms significantly associated to chronic granulomatous disease osteomyelitis in childhood. Clin. Infect. Dis. 46, 745-749 (2008).
17. Greenberg DE, Ding L, Zelazny AM et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog. 2, e28 (2006).
18. Santos PE, Piontelli E, Shea YR et al. Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease. Med. Mycol. 44, 749-753 (2006).
19. Bustamante J, Aksu G, De Beaucoudrey L et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J. Allergy Clin. Immunol. 120, 32-38 (2007).
20. Lau YL, Chan GC, Ha SY, Hui YF et al. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin. Infect. Dis. 26, 226-227 (1998).
21. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J. Clin. Immunol. (Suppl. 1), S67-S72 (2008).
22. Schäppi MG, Jaquet V, Belli DC, Krause KH. Hyperinflammation in chronic granulomatous disease and antiinflammatory role of the phagocyte NADPH oxidase. Semin. Immunopathol. 30, 255-271 (2008).
23. Marciano BE, Rosenzweig SD, Kleiner DE et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 114, 462-468 (2004).
24. Schappi MG, Smith VV, Goldblatt D, Lindley KJ, Milla PJ. Colitis in chronic granulomatous disease. Arch. Dis. Child. 84, 147-151 (2001).
25. Barton LL, Moussa SL, Villar RG, Hulett RL. Gastrointestinal complications of chronic granulomatous disease: case report and literature review. Clin. Pediatr. (Phila.) 37, 231-236 (1998).
26. Myrup B, Valerius NH, Mortensen PB. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 42, 127-130 (1998).
27. Feld JJ, Hussain N, Wright EC et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology (2008) (Epub ahead of print).
28. Walther MM, Malech HL, Berman A et al. The urologic manifestations of chronic granulomatous disease. J. Urol. 147, 1314-1318 (1992).
29. Chin TW, Stiehm ER, Faloon J et al. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J. Pediatr. 111, 349-352 (1987).
30. Quie PG, Belani KK. Corticosteroids for chronic granulomatous disease. J. Pediatr. 111, 393-394 (1987).
31. Southwick FS, Van Der Meer JWM. Recurrent cystitis and bladder mass in two adults with chronic granulomatosis. Ann. Intern. Med. 109, 118-121 (1988).
32. Goldblatt D, Butcher J, Thrasher AJ et al. Chorioretinal lesions in patients and carriers of chronic granulomatous disease. J. Pediatr. 134, 780-783 (1999).
33. Kim SJ, Kim JG, Yu YS. Chorioretinal lesions in patients with chronic granulomatous disease. Retina 23, 360-365 (2003).
34. Valluri S, Chu FC, Smith ME. Ocular pathologic findings of chronic granulomatous disease of childhood. Am. J. Ophthalmol. 120, 120-123 (1995).
35. Manzi S, Urbach AH, McCune AB et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum. 34, 101-105 (1991).
36. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin. Exp. Immunol. 148, 79-84 (2007).
37. Marsh WL, Oyen R, Nichols ME et al. Chronic granulomatous disease and the Kell blood groups. Br. J. Haematol. 29, 247-262 (1975).
38. Frey D, Machler M, Seger R et al. Gene deletion in a patient with chronic granulomatous disease and McLeod syndrome: fine mapping of the Xk gene locus. Blood 71, 252-255 (1988).
39. Vowells SJ, Sekhsaria S, Malech HL et al. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J. Immunol. Methods 178, 89-97 (1995).
40. Vowells SJ, Fleisher TA, Sekhsaria S et al. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J. Pediatr. 128, 104-107 (1996).
41. Roos D, Van Zwieten R, Wijnen JT et al. Molecular basis and enzymatic properties of glucose-6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 94, 2955-2962 (1999).
42. Whitin JC, Cohen HJ. Disorders of respiratory burst. Hematol. Oncol. Clin. North Am. 2, 289-299 (1988).
43. Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J. Pediatr. 139, 79-84 (2001).
44. Banerjee R, Anguita J, Roos D et al. Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox. J. Immunol. 164, 3946-3949 (2000).
45. Margolis DM, Melnick DA, Alling DW et al. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J. Infect. Dis. 162, 723-726 (1990).
46. Gallin JI, Alling DW, Malech HL et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 248, 2416-2422 (2003).
47. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324, 509-516 (1991).
48. Marciano BE, Wesley R, De Carlo ES et al. Long-term interferon therapy for patients with chronic granulomatous disease. Clin. Infect. Dis. 39, 692-699 (2004).
49. Philipart AL, Colodny AH, Baehner RL. Continuous antibiotic therapy in chronic granulomatous disease: preliminary communication. Pediatrics 50, 923-925 (1972).
50. Kobayashi Y, Ameno D, Ueda K et al. Treatment of seven cases of chronic granulomatous disease with sulfamethoxazole-trimethoprim (SMXTMP). Eur. J. Ped. 127, 247-254 (1978).
51. Lublin M, Bartlett DL, Danforth DN et al. Hepatic abscess in patients with chronic granulomatous disease. Ann. Surg. 235, 383-391(2002).
52. Petropoulou T, Liese J, Tintelnot K et al. Long-term treatment of patients with itraconazole for the prevention of Aspergillus infections in patients with chronic granulomatous disease (CGD). Mycoses 37(Suppl. 2), 64-69 (1994).
53. Mouy R, Veber F, Blanche S et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirtytwo patients with chronic granulomatous disease. J. Pediatr. 125, 998-1003 (1994).
54. Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin. Exp. Immunol. 120, 351-355 (2000).
55. Alsultan A, Williams MS, Lubner S et al. Chronic granulomatous disease presenting with disseminated intracranial aspergillosis. Pediatr. Blood Cancer 47, 107-110 (2006).
56. Segal BH, Barnhart LA, Anderson VL et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. 40, 1684 (2005).
57. Martire B, Rondelli R, Soresina A et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin. Immunol. 126, 155-164 (2008).
58. Liese J, Kloos S, Jendrossek V et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J. Pediatr. 137, 687-693 (2000).
59. Sierre S, Lipsich J, Santos P et al. Pulmonary fungal infection diagnosis in chronic granulomatous disease patients. Pediatr. Pulmonol. 42, 851-852 (2007).
60. Siddiqui S, Anderson VL, Hilligoss DM et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin. Infect. Dis. 45, 673-681 (2007).
61. Yomtovian R, Abramson J, Quie P, McCullough J. Granulocyte transfusion therapy in chronic granulomatous disease. Report of a patient and review of the literature. Transfusion 21, 739-743 (1981).
62. Von Planta M, Ozsahin H, Schroten H et al. Greater omentum flaps and granulocyte transfusions as combined therapy of liver abscess in chronic granulomatous disease. Eur. J. Pediatr. Surg. 7, 234-236 (1997).
63. Ozsahin H, Von Planta M, Muller I et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 92, 2719-2724 (1998).
64. Ikinciogullari A, Dogu F, Solaz N et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther. Apher. Dial. 9, 137-141 (2005).
65. Bielorai B, Toren A, Wolach B et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation. Bone Marrow Transplant. 26, 1025-1028 (2000).
66. Seger RA, Gungor T, Belohradsky BH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 100, 4344-4350 (2002).
67. Horwitz ME, Barrett AJ, Brown MR et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N. Engl. J. Med. 344, 881-888 (2001).
68. Malech HL, Maples PB, Whiting-Theobald N et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl Acad. Sci. USA 94, 12133-12138 (1997).
69. Weil WM, Linton GF, Whiting- TheobaldN et al. Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer. Blood 89, 1754-1761 (1997).
70. Dinauer MC, Li LL, Bjorgvinsdottir H et al. Long-term correction of phagocyte NADPH oxidase activity by retroviralmediated gene transfer in murine X-linked chronic granulomatous disease. Blood 94, 914-922 (1999).
71. Ott MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409 (2006).
72. Ott MG, Seger R, Stein S et al. AdVan ces in the treatment of chronic granulomatous disease by gene therapy. Curr. Gene Ther. 7, 155-161 (2007).
73. Roesler J, Koch A, Pörksen G et al. Benefit assessment of preventive medical check-ups in patients suffering from chronic granulomatous disease (CGD). J. Eval. Clin. Pract. 11, 513-521 (2005).
74. Jackson SH, Devadas S, Kwon J et al. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat. Immunol. 5, 818-827 (2004).
75. Bleesing JJ, Souto-Carneiro MM, Savage WJ et al. Patients with chronic granulomatous disease have a reduced peripheral blood memory B cell compartment. J. Immunol. 176, 7096-8103 (2006).
76. Mantegazza AR, Savina A, Vermeulen M et al. NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood (Epub ahead of print) (2008).
77. Romani L, Fallarino F, De Luca A et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451, 211-215 (2008).